Verastem, Inc. (VSTM) [Rocket]

Date Filed	Type	Description
06/15/2018	GN	Factors of Influence in 2018, Key Indicators and Opportunity within Companhia Brasileira de Distribuicao, SiteOne Landscape Supply, UGI, Versum Materials, Verastem, and Tanger Factory Outlet Centers — New Research Emphasizes Economic Growth
05/03/2018	BW	Verastem Oncology Reports First Quarter 2018 Financial Results
03/14/2018	BW	Verastem to Present at Upcoming Conferences
03/13/2018	BW	Verastem Reports Year-End 2017 Financial Results
02/09/2018	GN	Research Report Identifies Ichor, TASER International, Premier, NuVasive, Verastem, and BLACKLINE INC with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
12/15/2017	BW	Verastem Announces Pricing of Public Offering of Common Stock
12/10/2017	BW	Verastem Announces Clinical Data from the Pivotal Phase 3 DUO™ Study: Duvelisib Significantly Improves Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/05/2017	BW	Verastem to Present Results from Pivotal Phase 3 DUO Study in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at a Research and Development Event at ASH 2017
11/20/2017	GN	Research Report Identifies Hill-Rom, TASER International, Synchronoss Technologies, NuVasive, Verastem, and Roku with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
11/07/2017	BW	Verastem Reports Third Quarter 2017 Financial Results
09/22/2017	BW	Verastem to Present at the Cantor Fitzgerald Global Healthcare Conference
09/06/2017	BW	Verastem Expands Duvelisib Development Program to Include Peripheral T-Cell Lymphoma
09/06/2017	BW	Verastem Announces Positive Top-line Data from the Pivotal Phase 3 DUO™ Study in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
08/08/2017	BW	Verastem Reports Second Quarter 2017 Financial Results
05/31/2017	BW	Verastem to Present at the Jefferies 2017 Global Healthcare Conference
05/10/2017	BW	Verastem Reports First Quarter 2017 Financial Results